valsartan has been researched along with Ventricular Dysfunction in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, Q; Li, G; Li, Y; Liu, T; Shao, S; Suo, Y; Wang, Y; Yang, Q; Yuan, M; Zhang, Y | 1 |
| Chen, A; Chen, Z; Dong, Z; Fu, M; Ge, J; Hu, K; Qian, J; Sun, A; Xia, Y; Yang, X; Zou, Y | 1 |
| Asselin, CY; Cheung, D; Czaykowski, P; Dingman, B; Edel, A; Goyal, V; Jassal, DS; Kim, E; Mittal, I; Mozolevska, V; Ravandi, A; Schwartz, A; Shaikh, B; Singal, PK; Thliveris, J | 1 |
| Oliveira, GH; Robinson, MR | 1 |
| Arnold, JM; Artis, E; Aurigemma, G; Daley, WL; Janardhanan, R; Mulvagh, SL; Naqvi, TZ; Purkayastha, D; Solomon, SD; Thomas, JD; Zile, M | 1 |
| Al-Khatib, SM; Califf, RM; Kober, L; Lokhnygina, Y; McMurray, JJ; Solomon, SD; Thomas, KL; Velazquez, EJ | 1 |
1 review(s) available for valsartan and Ventricular Dysfunction
| Article | Year |
|---|---|
Contemporary clinical trial updates in heart failure.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Antihypertensive Agents; Biphenyl Compounds; Drug Combinations; Heart Failure; Heart Rate; Humans; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction | 2016 |
1 trial(s) available for valsartan and Ventricular Dysfunction
| Article | Year |
|---|---|
Amiodarone use after acute myocardial infarction complicated by heart failure and/or left ventricular dysfunction may be associated with excess mortality.
Topics: Aged; Amiodarone; Captopril; Cause of Death; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Probability; Proportional Hazards Models; Reference Values; Risk Assessment; Severity of Illness Index; Survival Analysis; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Dysfunction | 2008 |
4 other study(ies) available for valsartan and Ventricular Dysfunction
| Article | Year |
|---|---|
Angiotensin receptor-neprilysin inhibitor attenuates cardiac hypertrophy and improves diastolic dysfunction in a mouse model of heart failure with preserved ejection fraction.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cardiomegaly; Diastole; Disease Models, Animal; Drug Combinations; Heart Failure; Mice; Neprilysin; Receptors, Angiotensin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Dysfunction | 2022 |
LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Apoptosis; Biphenyl Compounds; Cardiomyopathy, Dilated; Cells, Cultured; Disease Models, Animal; Doxorubicin; Drug Combinations; Dynamins; Echocardiography; Female; Gene Expression; Humans; Male; Mice; Mitochondria; Myocytes, Cardiac; Tetrazoles; Valsartan; Ventricular Dysfunction | 2017 |
Role of renin-angiotensin system antagonists in the prevention of bevacizumab- and sunitinib-mediated cardiac dysfunction.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Antineoplastic Agents; Bevacizumab; Cardiotoxicity; Fumarates; Hydralazine; Male; Mice; Mice, Inbred C57BL; Perindopril; Renin-Angiotensin System; Sunitinib; Valsartan; Ventricular Dysfunction | 2019 |
Rationale and design: the VALsartan In Diastolic Dysfunction (VALIDD) Trial: evolving the management of diastolic dysfunction in hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Comorbidity; Diastole; Double-Blind Method; Echocardiography, Doppler; Humans; Hypertension; Randomized Controlled Trials as Topic; Research Design; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction | 2006 |